CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 103 enrolled
Drug / intervention
Belladonna and Opium Suppositories +1 moredrug
Likely dose
Belladonna and Opium Suppositories 16.2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01150474
NCT01150474Phase 4Completed
CompareCT.gov

Randomized Clinical Trial of Postoperative Belladonna and Morphine Suppositories in Vaginal Surgery

Kristina A. Butler·interventional·Posted Jun 25, 2010·Updated Jan 7, 2015

In Brief

A Phase 4 clinical trial evaluating Belladonna and Opium Suppositories and Placebo Suppositories for Vaginal Surgery. Completed, enrolled 103 participants across 1 site.

Detailed Summary

Our primary aim is to determine whether the routine use of belladonna and morphine suppositories will improve pain control following vaginal surgery. Treatment will begin immediately following surgery and every 8 hours for 16 hours.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaginal Surgery
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2010
Enrollment StartJan 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.0 years ago

Interventions

Belladonna and Opium Suppositoriesdrug

Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.

Placebo Suppositoriesdrug

Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.